Just a few neoantigens may be enough for T cells to control

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

Neoantigen driven B cell and CD4+ T follicular helper cell collaboration promotes robust anti-tumor CD8+ T cell responses

Biologics, Free Full-Text

What is neoantigen-based therapy?

What are Cancer Neoantigens? The Link Between Neoantigens and Immunotherapy – What's New in GU?

Subcellular location of source proteins improves prediction of neoantigens for immunotherapy

Neoantigen Cancer Vaccines & Companies Bringing it to the Market: Next Big Immunotherapy Breakthrough

Frontiers The Ways of Isolating Neoantigen-Specific T Cells

Manufacturing Personalised Cancer Vaccines

Induction of neoantigen-reactive T cells from healthy donors

Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer - ScienceDirect

Neoantigens and their potential applications in tumor immunotherapy (Review)

Just a few neoantigens may be enough for T cells to control prostate cancer